We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this data will help inform understanding of current use of emicizumab in infants and young children as a form of primary prophylaxis, especially when venous access has historically been a limiting factor.
Hemophilia A
We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this data will help inform understanding of current use of emicizumab in infants and young children as a form of primary prophylaxis, especially when venous access has historically been a limiting factor.
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
-
Connecticut Children's Hemophilia Treatment Center, Hartford, Connecticut, United States, 06106
Yale Hemophilia Treatment Center, New Haven, Connecticut, United States, 06510
Massachusetts General Comprehensive Hemophilia and Thrombosis Treatment Center, Boston, Massachusetts, United States, 02114
Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States, 03766
Rutgers Hemophilia Treatment Center, New Brunswick, New Jersey, United States, 08901
Newark Beth Israel, Newark, New Jersey, United States, 07112
Children's Hospital at Montefiore, Bronx, New York, United States, 10467
Western NY Blood Care - Research Foundation for SUNY, Buffalo, New York, United States, 14202
Regional Comprehensive Hemophilia Treatment Center (Mount Sinai), New York, New York, United States, 10029
Comprehensive Center for Hemophilia and Coagulation Disorders (Cornell), New York, New York, United States, 10065
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to 36 Months
ALL
No
Montefiore Medical Center,
Jennifer Davila, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital at Montefiore
2025-08